COVID-19 IgG seropositivity and its determinants in occupational groups of varying infection risks in two Andean cities of Ecuador before mass vaccination

PLoS One. 2024 Aug 29;19(8):e0309466. doi: 10.1371/journal.pone.0309466. eCollection 2024.

Abstract

Background: The COVID-19 pandemic has caused over 68.7 million infections and 1.35 million deaths in South America. There are limited data on SARS-CoV-2 seropositivity and its determinants from Andean countries prior to mass vaccinations against COVID-19.

Objective: To estimate SARS-CoV-2 seropositivity and its determinants before vaccination in occupational groups of adults presumed to have different levels of exposure and associations with potential symptomatology.

Methods: We measured seropositivity of anti-SARS-CoV-2 IgG antibodies in a cross-sectional study of vaccine-naïve adults aged 18 years and older, recruited within three occupational risk groups (defined as low [LR], moderate [MR], and high [HR]) between January and September 2021 in two Andean cities in Ecuador. Associations with risk factors were estimated using logistic regression.

Results: In a sample of 882 adults, IgG seropositivity for the three different occupational risk groups was 39.9% (CI 95% 35.3-44.6), 74.6% (CI 95% 66.4-81.4), and 39.0% (CI 95% 34.0-44.4) for the HR, MR, and LR groups, respectively. History of an illness with loss of taste and/or smell was significantly associated with seropositivity in all occupational groups, with adjusted ORs of 14.31 (95%CI, 5.83-35.12; p<0.001), 14.34 (95%CI 3.01-68.42; p<0.001), and 8.79 (95%CI 2.69-28.72; p<0.001), for the HR, MR, and LR groups, respectively; while fever was significant for the LR group with an adjusted OR of 1.24 (95%CI, 1.11-4.57; p = 0.025) and myalgia for the HR group with an adjusted OR of 2.07 (95%CI, 1.13-3.81; p = 0.019).

Conclusion: Notable proportions of seropositivity were seen in all occupational groups between January and September 2021 prior to mass vaccination. Loss of taste and/or smell was strongly associated with presence of anti-SARS-CoV-2 IgG antibodies irrespective of presumed occupational exposure risk.

MeSH terms

  • Adolescent
  • Adult
  • Antibodies, Viral* / blood
  • Antibodies, Viral* / immunology
  • COVID-19 Vaccines / administration & dosage
  • COVID-19 Vaccines / immunology
  • COVID-19* / epidemiology
  • COVID-19* / immunology
  • Cities / epidemiology
  • Cross-Sectional Studies
  • Ecuador / epidemiology
  • Female
  • Humans
  • Immunoglobulin G* / blood
  • Immunoglobulin G* / immunology
  • Male
  • Mass Vaccination / statistics & numerical data
  • Middle Aged
  • Occupational Exposure
  • Risk Factors
  • SARS-CoV-2* / immunology
  • Young Adult

Substances

  • Immunoglobulin G
  • Antibodies, Viral
  • COVID-19 Vaccines

Grants and funding

This study was funded by the following grants: Universidad Internacional del Ecuador, Grants No. UIDE-DGIP-MAT-PROY-20-003; 21-007; 21-008 awarded to JELR, NRS, and PC. Corporación Ecuatoriana para el Desarrollo de la Investigación y Academia (CEDIA) Grant Number: CEPRA XVI-2022-17 ANTICUERPOS IGG IGA fund awarded to JELR, RR, PJ, and NRS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.